Neoadjuvant pembrolizumab achieved a 71% pCR rate in desmoplastic melanoma, surpassing expectations for neoadjuvant anti–PD-1 treatment. The 3-year relapse-free survival rate was 74%, and the overall ...
Last week was a hellscape for vaccines, with a RICO lawsuit against the AAP and the newly antivax CDC coming for your HPV and polio vaccines.